N
TCRT icon

Nuveen’s Alaunos Therapeutics TCRT Stock Holding History

Nuveen’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,630
Closed -$2.04M – 3472
2022
Q1 		$2.04M Buy
18,630
+5,057
+37% +$649K ﹤0.01% 2493
2021
Q4 		$2.3M Buy
13,573
+5,388
+66% +$1.18M ﹤0.01% 2504
2021
Q3 		$2.23M Buy
8,185
+33
+0.4% +$10.1K ﹤0.01% 2617
2021
Q2 		$3.23M Buy
8,152
+2,326
+40% +$1.09M ﹤0.01% 2476
2021
Q1 		$3.15M Sell
5,826
-134
-2% -$83.4K ﹤0.01% 2400
2020
Q4 		$2.25M Sell
5,960
-675
-10% -$268K ﹤0.01% 2446
2020
Q3 		$2.51M Sell
6,635
-488
-7% -$216K ﹤0.01% 2275
2020
Q2 		$3.5M Buy
7,123
+1,717
+32% +$766K ﹤0.01% 2082
2020
Q1 		$1.99M Buy
5,406
+554
+11% +$287K ﹤0.01% 2191
2019
Q4 		$3.44M Sell
4,852
-52
-1% -$35.8K ﹤0.01% 2184
2019
Q3 		$3.15M Buy
4,904
+272
+6% +$216K ﹤0.01% 2192
2019
Q2 		$4.05M Buy
+4,632
New +$3.19M ﹤0.01% 2098

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nuveen's TCRT Position: Q2 2022 in Review

Nuveen sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 18,630 shares — an estimated $2.04M sold.

Nuveen first reported a position in TCRT in Q2 2019 and held it in 12 quarters. The position peaked at $4.05M in Q2 2019. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Nuveen reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 18,630 Alaunos Therapeutics shares in Q2 2022, an estimated $2.04M.
  • Nuveen first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 12 quarters.
  • Nuveen's Alaunos Therapeutics position peaked at $4.05M in Q2 2019.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.